Interpace Diagnostics Group (NASDAQ:IDXG) will post its quarterly earnings results before the market opens on Tuesday, August 13th. Analysts expect Interpace Diagnostics Group to post earnings of ($0.06) per share for the quarter. Interpace Diagnostics Group has set its FY 2019 guidance at EPS.
Interpace Diagnostics Group (NASDAQ:IDXG) last announced its quarterly earnings data on Monday, May 13th. The business services provider reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The business had revenue of $6.01 million during the quarter, compared to analyst estimates of $6.10 million. Interpace Diagnostics Group had a negative return on equity of 34.69% and a negative net margin of 53.75%. On average, analysts expect Interpace Diagnostics Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of IDXG opened at $0.84 on Wednesday. The stock has a 50 day simple moving average of $0.78. The firm has a market cap of $32.76 million, a PE ratio of -1.91 and a beta of 2.17. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.26 and a quick ratio of 2.26. Interpace Diagnostics Group has a 12-month low of $0.67 and a 12-month high of $1.78.
Separately, HC Wainwright set a $2.00 price objective on shares of Interpace Diagnostics Group and gave the stock a “buy” rating in a research note on Friday, July 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $2.81.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Featured Story: Quiet Period
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.